🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/06/2022 19,50 20,62 19,14 20,55 +6,81% 7,59% 881.200
01/06/2022 19,18 19,63 18,64 19,24 +1,53% 5,16% 580.100
31/05/2022 19,19 19,41 18,54 18,95 -1,25% 4,53% 622.300
27/05/2022 18,32 19,95 18,32 19,19 +5,44% 8,90% 1.749.400
26/05/2022 18,21 18,90 18,06 18,20 -0,11% 4,61% 1.058.700
25/05/2022 17,99 19,00 17,99 18,22 +1,50% 5,61% 953.200
24/05/2022 18,68 18,85 17,82 17,95 -5,92% 5,54% 861.600
23/05/2022 19,18 19,53 18,65 19,08 +0,85% 4,59% 963.500
20/05/2022 19,07 19,22 17,83 18,92 +2,27% 7,26% 1.041.300
19/05/2022 18,72 19,94 18,49 18,50 -1,96% 7,75% 1.455.600
18/05/2022 20,14 20,47 18,74 18,87 -10,10% 8,59% 975.400
17/05/2022 20,30 21,37 20,11 20,99 +6,06% 6,21% 925.700
16/05/2022 19,40 20,97 18,73 19,79 +2,17% 11,55% 1.321.400
13/05/2022 18,89 19,80 18,33 19,37 +5,39% 7,78% 1.826.100
12/05/2022 17,04 18,54 17,00 18,38 +6,67% 9,04% 3.397.200
11/05/2022 17,00 18,00 16,74 17,23 -28,24% 7,41% 8.205.600
10/05/2022 23,86 25,72 22,99 24,01 +11,67% 11,44% 2.048.400
09/05/2022 21,10 21,65 20,49 21,50 +0,23% 5,47% 1.760.200
06/05/2022 22,76 22,93 21,15 21,45 -5,96% 7,82% 1.062.200
05/05/2022 24,60 24,90 22,48 22,81 -9,23% 9,84% 1.173.700
04/05/2022 24,84 25,23 23,10 25,13 +1,78% 8,57% 830.100
03/05/2022 25,02 25,99 24,50 24,69 -2,53% 5,96% 497.600
02/05/2022 24,04 25,38 23,51 25,33 +4,63% 7,78% 1.047.700
29/04/2022 25,07 26,12 24,04 24,21 -2,69% 8,28% 742.600
28/04/2022 25,19 25,39 24,36 24,88 -0,40% 4,09% 1.420.700
27/04/2022 25,45 25,75 24,32 24,98 -1,77% 5,62% 630.500
26/04/2022 26,86 26,90 25,36 25,43 -6,88% 5,73% 782.500
25/04/2022 27,45 27,80 26,72 27,31 -0,33% 3,93% 603.400
22/04/2022 29,08 29,58 27,33 27,40 -6,55% 7,74% 1.074.100
21/04/2022 31,52 31,70 29,21 29,32 -6,18% 7,90% 640.500